Hoba Therapeutics Revenue
Biotechnology Research • 
Copenhagen, Capital Region of Denmark, Denmark • 11-20 Employees
Hoba Therapeutics revenue & valuation
| Annual revenue | $1,197,770 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,900,000 |
| Total funding | $27,700,000 |
Key Contacts at Hoba Therapeutics
Torsten Madsen
Chief Executive Officer
Kenneth Ahrend Petersen
Coo And Founder
Lone Fjord-Larsen
Senior Director, Nonclinical Development
Company overview
| Headquarters | Copenhagen, Capital Region of Denmark, Denmark |
| Phone number | +4538231170 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biotechnology, Pain, Pharmaceutical Industry, Hearing Loss, Biologics, CNS, Cipn, Neurophatic Pain |
| Founded | 2016 |
| Employees | 11-20 |
| Socials |
Hoba Therapeutics Email Formats
Hoba Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About Hoba Therapeutics
Hoba Therapeutics is a Danish biotech developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide. Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease. The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage. Hoba Therapeutics was founded in 2016 by Novo Holdings and Borean Innovation. Hoba Therapeutics received the Accelerator grant from the European Innovation Council in 2021 and the Grand Solution grant from Innovation Fund Denmark in 2018. About chronic neuropathic pain: Chronic neuropathic pain is a significant global health issue, affecting a substantial portion of the population worldwide. In Europe, the prevalence is estimated to be 6–8% of the general population. Chronic neuropathic pain represents an enormous personal and economic burden. Neuropathic pain is a chronic disorder resulting from damage or dysfunction of the nervous system. Causative factors are lesions in or disorders of the nervous system, such as injury, pressure, toxic agents (e.g., chemotherapy), viral infections, and metabolic disorders. These lesions lead to aberrant functioning of sensory nerve cells, resulting in a chronic, debilitating sensation of pain. The complexity and variability of chronic neuropathic pain necessitates a multifaceted treatment approach and highlights the need for a more effective and safer treatment options. The global neuropathic pain market is estimated to be valued at USD 7.6 bn.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Hoba Therapeutics has 5 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Hoba Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Hoba Therapeutics Tech Stack
Discover the technologies and tools that power Hoba Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Performance
Ecommerce
Mobile frameworks
JavaScript libraries
Maps
Hosting
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
South Africa
United Kingdom
United States
SingaporeFrequently asked questions
4.8
40,000 users
